^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FLT3-TKD mutation

i
Entrez ID:
Related tests:
Phase 1
H. Lee Moffitt Cancer Center and Research Insti...
Recruiting
Last update posted :
06/13/2024
Initiation :
08/23/2021
Primary completion :
08/01/2024
Completion :
08/01/2025
FLT3
|
FLT3-ITD mutation • FLT3-TKD mutation
|
Xospata (gilteritinib) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
Phase 2
National Cancer Institute (NCI)
Not yet recruiting
Last update posted :
03/01/2024
Initiation :
05/30/2024
Primary completion :
12/31/2025
Completion :
12/31/2025
TP53 • FLT3 • NPM1 • RUNX1 • ASXL1 • RARA • RUNX1T1 • PML • CEBPA
|
TP53 mutation • FLT3-ITD mutation • NPM1 mutation • RUNX1 mutation • ASXL1 mutation • FLT3-TKD mutation • CEBPA mutation
|
Venclexta (venetoclax) • cytarabine • azacitidine • daunorubicin • Starasid (cytarabine ocfosfate)
Phase 2
Centre Antoine Lacassagne
Recruiting
Last update posted :
11/10/2023
Initiation :
06/03/2023
Primary completion :
03/15/2027
Completion :
03/15/2027
FLT3 • CD33
|
FLT3-ITD mutation • FLT3-TKD mutation • CD33 positive
|
cytarabine • Xospata (gilteritinib) • Mylotarg (gemtuzumab ozogamicin)
Phase 3
Stichting Hemato-Oncologie voor Volwassenen Ned...
Active, not recruiting
Last update posted :
06/15/2023
Initiation :
12/20/2019
Primary completion :
12/01/2024
Completion :
06/01/2033
FLT3
|
FLT3-ITD mutation • FLT3 mutation • FLT3-TKD mutation
|
Xospata (gilteritinib) • Rydapt (midostaurin)
Phase 1
Ayman H Qasrawi
Withdrawn
Last update posted :
04/25/2023
Initiation :
03/01/2023
Primary completion :
05/30/2027
Completion :
05/30/2032
FLT3
|
FLT3-ITD mutation • FLT3-TKD mutation
|
cytarabine • Xospata (gilteritinib) • mitoxantrone • cladribine • Neupogen (filgrastim)